RU2753493C2 - Анти-ох40 антитела и их применение - Google Patents

Анти-ох40 антитела и их применение Download PDF

Info

Publication number
RU2753493C2
RU2753493C2 RU2019121895A RU2019121895A RU2753493C2 RU 2753493 C2 RU2753493 C2 RU 2753493C2 RU 2019121895 A RU2019121895 A RU 2019121895A RU 2019121895 A RU2019121895 A RU 2019121895A RU 2753493 C2 RU2753493 C2 RU 2753493C2
Authority
RU
Russia
Prior art keywords
ser
leu
thr
gly
val
Prior art date
Application number
RU2019121895A
Other languages
English (en)
Russian (ru)
Other versions
RU2019121895A (ru
RU2019121895A3 (enExample
Inventor
Фиона А. ХАРДИНГ
Original Assignee
Эббви Байотерапьютикс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эббви Байотерапьютикс Инк. filed Critical Эббви Байотерапьютикс Инк.
Publication of RU2019121895A publication Critical patent/RU2019121895A/ru
Publication of RU2019121895A3 publication Critical patent/RU2019121895A3/ru
Application granted granted Critical
Publication of RU2753493C2 publication Critical patent/RU2753493C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2019121895A 2016-12-15 2017-12-15 Анти-ох40 антитела и их применение RU2753493C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662434761P 2016-12-15 2016-12-15
US62/434,761 2016-12-15
PCT/US2017/066680 WO2018112346A1 (en) 2016-12-15 2017-12-15 Anti-ox40 antibodies and their uses

Publications (3)

Publication Number Publication Date
RU2019121895A RU2019121895A (ru) 2021-01-15
RU2019121895A3 RU2019121895A3 (enExample) 2021-02-15
RU2753493C2 true RU2753493C2 (ru) 2021-08-17

Family

ID=60937946

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019121895A RU2753493C2 (ru) 2016-12-15 2017-12-15 Анти-ох40 антитела и их применение

Country Status (37)

Country Link
US (7) US10556962B2 (enExample)
EP (2) EP3504242B1 (enExample)
JP (2) JP6772385B2 (enExample)
KR (2) KR20210157471A (enExample)
CN (1) CN110573527A (enExample)
AR (1) AR110526A1 (enExample)
AU (1) AU2017377036B2 (enExample)
BR (2) BR112019012328A2 (enExample)
CA (1) CA3045940A1 (enExample)
CL (1) CL2019001646A1 (enExample)
CO (1) CO2019007288A2 (enExample)
CR (1) CR20190330A (enExample)
CY (1) CY1123274T1 (enExample)
DK (1) DK3504242T3 (enExample)
DO (1) DOP2019000165A (enExample)
EC (1) ECSP19050049A (enExample)
ES (1) ES2813057T3 (enExample)
HR (1) HRP20201259T1 (enExample)
HU (1) HUE050399T2 (enExample)
IL (1) IL267070A (enExample)
LT (1) LT3504242T (enExample)
MA (1) MA53184A (enExample)
MX (1) MX2019007121A (enExample)
MY (1) MY198059A (enExample)
PE (1) PE20191403A1 (enExample)
PH (1) PH12019501357A1 (enExample)
PL (1) PL3504242T3 (enExample)
PT (1) PT3504242T (enExample)
RS (1) RS60664B1 (enExample)
RU (1) RU2753493C2 (enExample)
SG (1) SG10201914126RA (enExample)
SI (1) SI3504242T1 (enExample)
SM (1) SMT202000462T1 (enExample)
TW (1) TWI734879B (enExample)
UA (1) UA125041C2 (enExample)
UY (1) UY37523A (enExample)
WO (1) WO2018112346A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210157471A (ko) * 2016-12-15 2021-12-28 애브비 바이오테라퓨틱스 인크. 항-ox40 항체 및 이의 용도
CA3066007A1 (en) * 2017-06-09 2018-12-13 Glaxosmithkline Intellectual Property Development Limited Combination therapy with icos agonist and ox40 agonist to treat cancer
US11242398B2 (en) * 2017-08-01 2022-02-08 Remd Biotherapeutics, Inc. Anti-OX40 antibodies and methods of activating OX40
CN110790837A (zh) * 2018-08-02 2020-02-14 上海君实生物医药科技股份有限公司 抗btla抗体
WO2020119789A1 (en) * 2018-12-14 2020-06-18 Wuxi Biologics (Shanghai) Co., Ltd. Fully human antibodies against ox40, method for preparing the same, and use thereof
EP3904383A4 (en) * 2018-12-25 2022-08-17 Hanx Biopharmaceutics, Inc ANTI-OX40 MONOCLONAL ANTIBODY AND USE THEREOF
CN110172090B (zh) * 2019-06-03 2020-04-03 中山标佳生物科技有限公司 Cd134单克隆抗体及其制备方法和癌症治疗中的应用
WO2021098851A1 (en) * 2019-11-20 2021-05-27 Eucure (Beijing) Biopharma Co., Ltd Anti-ctla4/ox40 bispecific antibodies and uses thereof
JP7755581B2 (ja) 2019-12-17 2025-10-16 アムジエン・インコーポレーテツド 治療における使用のためのデュアルインターロイキン－２／ｔｎｆ受容体アゴニスト
CN113045654A (zh) * 2019-12-27 2021-06-29 南开大学 抗ox40抗体及其用途
CN111303285B (zh) * 2019-12-27 2023-06-02 百力司康生物医药(杭州)有限公司 靶向ox40的抗体及其制备方法和应用
WO2021190431A1 (zh) * 2020-03-23 2021-09-30 百奥泰生物制药股份有限公司 一种免疫细胞激活剂的开发及应用
CA3175413A1 (en) * 2020-04-17 2021-10-21 Yizhen Yang Anti-ox40 antibody and uses thereof
CN115461371A (zh) * 2020-06-30 2022-12-09 和铂医药(上海)有限责任公司 靶向ox40的抗体及其制备方法和应用
AU2021313058A1 (en) * 2020-07-23 2023-03-30 Dyne Therapeutics, Inc. Muscle-targeting complexes and uses thereof
CN111704671B (zh) * 2020-08-19 2020-11-24 广东赛尔生物科技有限公司 Ox40抗体及其在治疗癌症中的应用
CN112442121A (zh) * 2020-08-20 2021-03-05 山东兴瑞生物科技有限公司 Ox40抗体、其编码基因、及抗体的制备方法和在增强人体免疫功能中的应用
CN114106173A (zh) * 2020-08-26 2022-03-01 上海泰槿生物技术有限公司 抗ox40抗体、其药物组合物及应用
CN111763258B (zh) * 2020-09-01 2020-12-29 北京百奥赛图基因生物技术有限公司 抗ox40抗体及其用途
CN114515335A (zh) * 2020-11-19 2022-05-20 百奥泰生物制药股份有限公司 抗ox40抗体在治疗肿瘤或癌症中的应用
JP2024508207A (ja) 2020-12-02 2024-02-26 ブイアイビー ブイゼットダブリュ がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト
CN115260312B (zh) * 2021-04-30 2025-02-14 保诺科技（北京）有限公司 结合ox40的抗体或抗原结合片段
CN118121694A (zh) * 2022-12-01 2024-06-04 北京东方百泰生物科技股份有限公司 一种抗Siglec-15单克隆抗体的注射制剂

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012027328A2 (en) * 2010-08-23 2012-03-01 Board Of Regents, The University Of Texas System Anti-ox40 antibodies and methods of using the same
RU2562874C1 (ru) * 2011-08-23 2015-09-10 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Антитела против ох40 и способы их применения
WO2016073380A1 (en) * 2014-11-03 2016-05-12 Genentech, Inc. Method and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
JP4312259B2 (ja) 1995-04-27 2009-08-12 アムジェン フレモント インク． 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
BRPI9809391B8 (pt) 1997-04-14 2021-05-25 Amgen Res Munich Gmbh processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AU2873999A (en) 1998-02-24 1999-09-06 Sisters Of Providence In Oregon Compositions containing an OX-40 receptor binding agent or nucleic acid encoding the same and methods for enhancing antigen-specific immune response
US6312700B1 (en) 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
JP2002530081A (ja) 1998-11-18 2002-09-17 ジェネンテック・インコーポレーテッド 親抗体より高度な結合親和性を持つ抗体変異体
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
CA2489004C (en) 2002-06-13 2013-01-08 Crucell Holland B.V. Agonistic binding molecules to the human ox40 receptor
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
TWI461436B (zh) * 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
US20080286286A1 (en) 2006-01-13 2008-11-20 Board Of Regents, The University Of Texas System Methods to Treat Disease States by Influencing the Signaling of Ox-40-Receptors and High Throughput Screening Methods for Identifying Substances Therefor
SG186656A1 (en) 2007-12-14 2013-01-30 Bristol Myers Squibb Co Binding molecules to the human ox40 receptor
MX368665B (es) 2013-03-15 2019-10-10 Abbvie Biotherapeutics Inc Variantes de fc.
KR20160006168A (ko) * 2013-03-18 2016-01-18 바이오서오엑스 프로덕스 비.브이. 인간화 항-cd134(ox40) 항체 및 이의 용도
RU2016142476A (ru) 2014-03-31 2018-05-07 Дженентек, Инк. Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
TW201619200A (zh) 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗－ｏｘ４０抗體及其用途
TWI716405B (zh) * 2015-05-07 2021-01-21 美商艾吉納斯公司 抗ox40抗體及其使用方法
RU2017142008A (ru) * 2015-05-21 2019-06-24 Эллигейтор Биосайенс Аб Новые полипептиды
US20160347848A1 (en) * 2015-05-28 2016-12-01 Medimmune Limited Therapeutic combinations and methods for treating neoplasia
EP3383914A4 (en) 2015-12-02 2019-10-30 Agenus Inc. ANTI-OX40 ANTIBODIES AND METHOD OF USE THEREOF
KR20210157471A (ko) * 2016-12-15 2021-12-28 애브비 바이오테라퓨틱스 인크. 항-ox40 항체 및 이의 용도

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012027328A2 (en) * 2010-08-23 2012-03-01 Board Of Regents, The University Of Texas System Anti-ox40 antibodies and methods of using the same
RU2562874C1 (ru) * 2011-08-23 2015-09-10 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Антитела против ох40 и способы их применения
WO2016073380A1 (en) * 2014-11-03 2016-05-12 Genentech, Inc. Method and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment

Also Published As

Publication number Publication date
US10604584B2 (en) 2020-03-31
CR20190330A (es) 2019-12-19
US20180346593A1 (en) 2018-12-06
PT3504242T (pt) 2020-08-26
KR20210157471A (ko) 2021-12-28
LT3504242T (lt) 2020-09-10
DK3504242T3 (da) 2020-08-17
US10556962B2 (en) 2020-02-11
CL2019001646A1 (es) 2019-08-23
PL3504242T3 (pl) 2020-11-16
AU2017377036A1 (en) 2019-07-11
CY1123274T1 (el) 2021-12-31
EP3504242A1 (en) 2019-07-03
WO2018112346A1 (en) 2018-06-21
AU2017377036B2 (en) 2022-06-23
RS60664B1 (sr) 2020-09-30
TW201825520A (zh) 2018-07-16
ES2813057T3 (es) 2021-03-22
US20220112304A1 (en) 2022-04-14
UA125041C2 (uk) 2021-12-29
MA53184A (fr) 2021-05-26
US10040864B2 (en) 2018-08-07
JP6772385B2 (ja) 2020-10-21
TWI734879B (zh) 2021-08-01
HRP20201259T1 (hr) 2020-11-13
ECSP19050049A (es) 2019-07-31
SMT202000462T1 (it) 2020-09-10
CN110573527A (zh) 2019-12-13
RU2019121895A (ru) 2021-01-15
US20200048363A1 (en) 2020-02-13
UY37523A (es) 2018-07-31
BR112019012328A2 (pt) 2019-11-19
SG10201914126RA (en) 2020-02-27
US20180194855A1 (en) 2018-07-12
IL267070A (en) 2019-08-29
KR102341926B1 (ko) 2021-12-23
EP3504242B1 (en) 2020-06-24
PE20191403A1 (es) 2019-10-04
AR110526A1 (es) 2019-04-10
JP2020504101A (ja) 2020-02-06
US20200181282A1 (en) 2020-06-11
DOP2019000165A (es) 2019-07-15
PH12019501357A1 (en) 2020-01-20
EP3725809A1 (en) 2020-10-21
SI3504242T1 (sl) 2020-10-30
CO2019007288A2 (es) 2019-08-20
US20180171023A1 (en) 2018-06-21
JP2021019603A (ja) 2021-02-18
KR20190092552A (ko) 2019-08-07
CA3045940A1 (en) 2018-06-21
US20210017289A1 (en) 2021-01-21
HUE050399T2 (hu) 2020-12-28
BR122020025629B1 (pt) 2022-05-31
MX2019007121A (es) 2020-02-05
MY198059A (en) 2023-07-31
RU2019121895A3 (enExample) 2021-02-15

Similar Documents

Publication Publication Date Title
RU2753493C2 (ru) Анти-ох40 антитела и их применение
US10233258B2 (en) Bispecific binding proteins that bind CD40 and mesothelin
KR102003754B1 (ko) Pd-l1 항체와 이를 이용한 치료 및 진단
US12435151B2 (en) Anti-TNFR2 antibodies and uses thereof
AU2022301381A1 (en) Anti-cd3 antibody and use thereof
CN119894934A (zh) 结合lilrb4和cd3的抗体及其用途
HK40029314A (en) Anti-ox40 antibodies and their uses
RU2811912C2 (ru) Антитела против альфа-субъединицы ил-7r и их применение
HK40003363A (en) Anti-ox40 antibodies and their uses
HK40003363B (en) Anti-ox40 antibodies and their uses
HK40005909B (en) Anti-pd-l1 antibodies and their use as therapeutics and diagnostics